To view this email as a web page, click here.

Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for mCRPC

A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for mCRPC.

Dr. Mehmet Sitki Copur on the Most Exciting Research Presented at ASCO 2019

Cancer Network spoke with Mehmet Sitki Copur, MD, FACP, medical oncologist at the Morrison Cancer Center, about the most exciting research presented at ASCO in 2019.

IN CASE YOU MISSED IT

Long-Awaited Results of Isatuximab Combo in R/R Myeloma Presented

Researchers evaluated survival and infusion time with combination isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide plus low-dose dexamethasone alone in relapsed or refractory multiple myeloma.

One FDA-Approved test analyzes 324 cancer-related genes

FoundationOne^®CDx analyzes all recommend genomic biomarkers for solid tumors, including companion diagnostic indications with direct paths to therapy. This one test can help guide therapy selection and clinical trial options for more patients.

Read more.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.